National prevalence of IC/BPS in women and men utilizing veterans health administration data.

Autor:	Anger JT; Department of Urology, UC San Diego Health, San Diego, CA, United States., Dallas KB; City of Hope Urology, Duarte, CA, United States., Bresee C; Department of Biostatistics and Bioinformatics Research Center, Cedars-Sinai Medical Center, Los Angeles, CA, United States., De Hoedt AM; Urology Section, Department of Surgery, Veterans Affairs Medical Centers Division of Population Health, Durham, NC, United States., Barbour KE; National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, United States., Hoggatt KJ; Center for Study of Healthcare Implementation, Innovation and Policy Veterans Health Administration, Los Angeles, CA, United States., Goodman MT; Cedars-Sinai Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States., Kim J; Cedars-Sinai Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.; Department of Surgery and Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, United States., Freedland SJ; Urology Section, Department of Surgery, Veterans Affairs Medical Centers Division of Population Health, Durham, NC, United States.; Cedars-Sinai Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, United States.; Department of Surgery and Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in pain research (Lausanne, Switzerland) [Front Pain Res (Lausanne)] 2022 Aug 24; Vol. 3, pp. 925834. Date of Electronic Publication: 2022 Aug 24 (Print Publication: 2022).
DOI:	10.3389/fpain.2022.925834
Abstrakt:	Importance: Interstitial cystitis/bladder pain syndrome (IC/BPS) is an immense burden to both patients and the American healthcare system; it is notoriously difficult to diagnose. Prevalence estimates vary widely (150-fold range in women and >500-fold range in men). Objectives: We aimed to create accurate national IC/BPS prevalence estimates by employing a novel methodology combining a national population-based dataset with individual chart abstraction. Study Design: In this epidemiological survey, all living patients, with ≥2 clinic visits from 2016 to 2018 in the Veterans Health Administration, with an ICD-9/10 code for IC/BPS ( n = 9,503) or similar conditions that may represent undiagnosed IC/BPS ( n = 124,331), were identified (other were controls n = 5,069,695). A detailed chart review of random gender-balanced samples confirmed the true presence of IC/PBS, which were then age- and gender-matched to the general US population. Results: Of the 5,203,529 patients identified, IC/BPS was confirmed in 541 of 1,647 sampled charts with an IC/BPS ICD code, 10 of 382 charts with an ICD-like code, and 3 of 916 controls. After age- and gender-matching to the general US population, this translated to national prevalence estimates of 0.87% (95% CI: 0.32, 1.42), with female and male prevalence of 1.08% (95% CI: 0.03, 2.13) and 0.66% (95% CI: 0.44, 0.87), respectively. Conclusions: We estimate the prevalence of IC/BPS to be 0.87%, which is lower than prior estimates based on survey data, but higher than prior estimates based on administrative data. These potentially represent the most accurate estimates to date, given the broader and more heterogeneous population studied and our novel methodology of combining in-depth chart abstraction with administrative data. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Anger, Dallas, Bresee, De Hoedt, Barbour, Hoggatt, Goodman, Kim and Freedland.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu